Ronel Veksler, co-founder and CEO of PromiseBio discusses his company’s AI-enabled proteomics platform, and how post-translational modifications of proteins represent a new frontier for precision medicine in autoimmune diseases. www.youtube.com/watch?v=jeJh...

Theresa Heah, CEO of Eyexora, discusses the hub-and-spoke business model, the company’s initial assets in-licensed from the Singapore Eye Research Institute, and how it identifies early-stage candidates with high potential. thebioreport.podbean.com/e/a-hub-and-...

Jeffrey Brown CSO of TriNetX, discusses how real-world data can address common challenges in rare disease research, the hurdles that need to be addressed, and how advances in AI could revolutionize rare disease research. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/tr...

Brian Weitzner, co-founder of OpenFold, discusses the collaborative effort to develop software and AI tools to predict the 3D structure of proteins, how its open licensing model ensures broad accessibility, and how it stacks up against AlphaFold. thebioreport.podbean.com/e/an-ai-coll...

Here's what you may have missed in October from The Bio Report, RARECast, and Life Sciences D'n'A podcasts. www.linkedin.com/pulse/why-us...

Prarthana Khanna, VP of corporate business development and strategy for Vico Therapeutics, discusses Huntington's disease, the company’s experimental ASO, and why it has the potential to address multiple neurological diseases. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/ta...

John Hoekman, co-founder and CEO of Junevity, discusses the role of transcription factors in healthy biology and aging-related disease, the company’s AI-driven platform, and its lead programs targeting type 2 diabetes and obesity. thebioreport.podbean.com/e/hitting-th...

Philippa Ward discusses her journey as the mother of a child diagnosed with tuberous sclerosis complex, the challenges posed by the condition’s complexities, and how she found both a community and her own voice as an advocate. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/le...

Aaron Cohen, Head of Research Oncology, Clinical Data at Flatiron Health, joins Amar Drawid, on Life Sciences DNA to explore how large language models are transforming oncology research. www.youtube.com/watch?v=W-Gq...

Stacy Lindborg, CEO of Imunon, discusses the company’s DNA-mediated immunotherapy, how it avoids the systemic toxicities that undermined earlier IL-12 approaches, and how it could change the treatment landscape for the disease. thebioreport.podbean.com/e/changing-t...

The Rwanda FDA approved @BioUsawa 's BioUcenta, a biosimilar of Lucentis. It is the first biosimilar ranibizumab approved in Africa and represents the first major regulatory milestone for Bio Usawa. www.globenewswire.com/news-release...

Laura Russo, U.S. patient engagement lead for Pfizer, discusses how the company’s patient-facing teams work to bridge health systems and patient communities to improve access and care. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/im...

Drew Endy, senior fellow of the Hoover Institution, discusses China’s all-of-nation strategy, how the United States has misallocated research dollars, and why a cultural embrace of biotechnology will be critical for the success of either country. thebioreport.podbean.com/e/why-the-un...

Kristin McKay, CEO of Project Alive, discusses the need for new therapies for Hunter syndrome, the importance of early detection, and the patient community’s concerns with regulatory delays in approving needed treatments. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/a-...

Arc Institute’s Hani Goodarzi, Ultima Genomics' Gilad Almogy, and 10X Genomics' Serge Saxonov discuss the ARC Virtual Cell Atlas, which uses single-cell genomics, AI, and open science to understand the complexities of cellular behavior. thebioreport.podbean.com/e/transformi...

Amélie Lothe, global medical community head for rare epilepsies at UCB, discusses the importance of looking beyond seizures to view developmental and epileptic encephalopathies as complex neurodevelopmental conditions. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/th...

Marc Salzberg, CEO of Airway Therapeutics, discusses the company’s experimental therapy zelpultide alfa to treat preterm infants with a rare lung disease, why it’s a pipeline-in-a-product, and its development path forward. thebioreport.podbean.com/e/scratching...

Here's what you may have missed in September from The Bio Report, RARECast, and Life Sciences D'n'A podcasts. www.linkedin.com/pulse/extend...

Todd Harris, CEO of Tyra Biosciences, discusses the company’s experimental oral medicine for achondroplasia, studies conducted to date, and why he believes it will offer competitive advantages over existing therapies. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/ta...

What happens when AI touches every role, every day, in clinical development? Stephen Pyke of @parexel.bsky.social, in conversation with Nagaraja Srivatsan, highlights why preparing teams early is essential to unlock their full potential. trials?https://www.youtube.com/watch?v=gNTNJhLfzT0&t=1s

Rohan Palekar, CEO of 89bio, discusses what’s driving the prevalence of MASH, the limits of existing medicines, and how the company’s experimental therapy targets both liver fibrosis and the underlying metabolic dysfunctions of the disease. thebioreport.podbean.com/e/a-dual-act...

Paul Peter Tak, president and CEO of Candel Therapeutics, discusses the company's viral immunotherapy for brain cancer, how it works, and what clinical studies have shown to date. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/65...

Steve Perrin, CSO of Eledon Pharmaceuticals, discusses the need for innovative approaches to immunosuppression in organ transplantation, how its experimental therapy works, and why it may have benefits in autoimmune and neurodegenerative diseases as well. thebioreport.podbean.com/e/extending-...

David Jenkinson of @lifearc.bsky.social discusses the children’s cancer therapeutics consortium C-Further, the challenges of developing treatments for childhood cancers, and why new models for advancing these therapies are needed. @globalgenes.bsky.social #RARECast open.spotify.com/episode/13td...

Mohan Uttarwar, CEO of @1Cell.Ai discusses how AI-powered cell biopsy could make cancer monitoring more accessible, minimally invasive, and transformative for millions of patients worldwide www.agilisium.com/podcast/tran...

Greg Mario, CEO of Taxis Pharmaceuticals, discusses the public health threat posed by drug-resistant gonorrhea, the approaches it’s taking to develop new antimicrobial treatments, and the need for new funding models to bring new therapies to market. thebioreport.podbean.com/e/overcoming...

Robin Williams of UofM Masonic Children's Hospital describes the medical mystery of a 15-year-old who became critically ill when he was admitted into a PICU and what it took to diagnose him with the ultra-rare disease TAFRO. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/so...

Marc Hedrick, president and CEO of Plus Therapeutics, Inc., discusses the challenges of treating brain tumors, the limitations of current therapies, and why the company’s targeted radiotherapies have the potential to create better outcomes for patients. thebioreport.podbean.com/e/using-targ...

Morten Graugaard, co-founder and CEO of Orbis Medicines, discusses its class of synthetic macrocycles, called nCycles, its platform technology for generating and screening these therapies, and how they can offer an orally delivered alternative to biologics. thebioreport.podbean.com/e/hitting-pr...

Tris Dyson, managing director of Challenge Works, discusses his diagnosis of ALS, the case for using a prize to spur innovation, and the potential for leveraging AI to find treatments for the disease. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/us...

Stacey Adam of the Foundation for the National Institutes of Health, discusses the public-private partnership she is leading to advance alternatives to animal testing, the technologies they are exploring, and their potential to accelerate drug development. thebioreport.podbean.com/e/building-b...

Daniel Fischer of Tevard Biosciences discusses his journey as the parent of a child with a rare disease, how it led to his co-founding Tevard, and its pursuit of tRNA therapies that may treat a range of diseases with a single drug. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/re...

Dimitris K. Agrafiotis, Director of Digital Analytics and AI at Arsenal Capital Partners discusses why AI will have a bigger near-term impact on improving operational overhead than on driving novel science. www.agilisium.com/podcast/why-...

Lorin Johnson of Glycyx discusses the effect of opioids on the immune system and the company’s experimental therapy designed to mitigate the negative effects of opioids in cancer patients being treated with checkpoint inhibitors. thebioreport.podbean.com/e/preventing...

Tien Lee, CEO of Aardvark Therapeutics, discusses Prader-Willi syndrome, the biological difference between hunger and appetite, and why his company’s experimental therapy may have broader applications in other forms of obesity. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/ta...

Abbas Kazimi, CEO Nimbus Therapeutics, discusses how the company’s drug discovery approach has evolved with AI, its deal making successes, and how its business model provides liquidity to investors and while making it easier to structure deals. thebioreport.podbean.com/e/better-liv...

Here's what you may have missed in July from The Bio Report, RARECast, Life Sciences D'n'A, and MitoCast podcasts. www.linkedin.com/pulse/new-ap...

David B. Goldstein, founder and CEO of Actio Biosciences, Inc., discusses the company’s rare-to-common business model, how it identifies the indications it will pursue, and why pricing may represent a challenge. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/a-...

Juho Jalkanen, founder and CEO of Faron, discusses how the tumor microenvironment can suppress macrophages, how the company’s macrophage checkpoint inhibitor works, and the challenges a Finland-based company faces accessing the capital markets. thebioreport.podbean.com/e/outsmartin...

Bio Usawa and Sartorius have announced a partnership to accelerate Africa’s biopharmaceutical industry and address the continent’s urgent, dual health burdens in infectious and non-communicable diseases. www.globenewswire.com/news-release...

NASA principal investigators Christopher Mason and Afshin Beheshti discuss the impact of space travel on mitochondria, why it represents a critical barrier for space travel, and why solving the problem may give us ways of extending healthy years of life on Earth. www.youtube.com/watch?v=ps4c...

Bio Usawa, a biotechnology company committed to manufacturing affordable monoclonal antibody therapies in Africa, announced a strategic partnership agreement with DEK to distribute Bio Usawa's products throughout Ghana and the broader West African region. www.globenewswire.com/news-release...

Khartik Uppalapati, co-founder of the RareGen Youth Network, discusses his journey as a rare disease patient, his work as an advocate, and why it's essential there be greater youth representation in healthcare policy and advocacy. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/le...

Sunil Talathi of BeOne Medicines sits down with Nagaraja Srivatsan to discuss his experience implementing AI in a biopharmaceutical company, prompt engineering, and the need for collaboration between humans and AI systems. www.youtube.com/watch?v=5lF_...

Bio Usawa and ServareGMP announced a strategic partnership to establish advanced monoclonal antibody manufacturing capabilities in Africa, directly addressing the critical healthcare access gap affecting patients in low- and middle-income countries. finance.yahoo.com/news/bio-usa...

Arun Upadhyay, CSO and head of R&D at Ocugen, discusses inherited retinal diseases, the company’s gene therapies that can work across different genetic mutations, and the potential of its platform technology beyond the eye. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/de...

Jenny Marlowe and Melissa Bonner of nChroma Bio discuss the company’s experimental epigenetic editor for hepatitis B, the merger that formed the company, and how it married an epigenetic editing platform with programmable non-viral delivery technologies. thebioreport.podbean.com/e/crafting-a...

Steve Mahoney, CEO of Viridian Therapeutics, discusses thyroid eye disease, the challenges of living with the condition, and why its veligrotug has the potential to provide a new alternative for people living with the condition. @globalgenes.bsky.social #RARECast globalgenes.org/raredaily/ey...

Craig Lipset, advisor and founder of Clinical Innovation Partners, discusses how AI can bring greater predictability to clinical trials, how organizations can effectively adopt the technology, and the importance of fostering a culture of experimentation. www.youtube.com/watch?v=Ka3U...

Niven Narain, CEO of BPGbio, discusses how the company’s platform technology uncovers novel targets, its evolution from its start as Berg, and how the platform continues to provide insight into experimental therapies after they advance to the clinic. thebioreport.podbean.com/e/fueling-ai...